Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03962998 · ClinicalTrials.gov registry record · Early Phase 1
Oral Administration of MB-102 Versus Dual Sugar Testing for Gut Permeability
A Early Phase 1 study of Crohn Disease, sponsored by MediBeacon.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 22
- Enrollment target
- 1
- Study location
NCT03962998: Completed Early Phase 1 study of Crohn Disease, sponsored by MediBeacon.
NCT03962998 is a Early Phase 1 study of Crohn Disease that has completed, run by MediBeacon. The registered enrollment target is 22 participants, below the 205-participant average among 71 other Crohn Disease trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03962998, a Early Phase 1 study of Crohn Disease, has completed, sponsored by MediBeacon.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 22 participants
- Enrollment target
- 1
- Study location
Study Summary
The objectives of the study are to evaluate the safety and tolerability of oral administration of MB-102, and to evaluate the use of MB-102 as a means of measuring gut permeability in normal participants (n=10) and in those with radiologic evidence of small bowel Crohn's disease (n=10).
Primary Outcome
Urine samples will be collected pre-dose (time 0), each time the participant voids, and at the protocol-defined time points after oral administration of MB-102. The total volume of urine excreted will be recorded. Urine samples will be analyzed using validated analytical methods.
Conditions Studied
Interventions
- DRUG Lactulose/Rhamnose solution
- DRUG MB-102
Study Locations (1)
Missouri
- Washington University in St. Louis - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2019-10-27 |
| Est. Completion | 2021-10-05 |
| Phase | Early Phase 1 |
What the finished NCT03962998 record still lists
NCT03962998 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 205-participant average among 71 other Crohn Disease trials with a reported enrollment target (89% lower).
The record links to 1 condition, with Crohn Disease appearing as the primary indexed condition, and to 2 interventions - of which Lactulose/Rhamnose solution is the first listed.
NCT03962998 reports a single indexed study location in Missouri.
Frequently Asked Questions
What is clinical trial NCT03962998 about?
NCT03962998 is a clinical study titled "Oral Administration of MB-102 Versus Dual Sugar Testing for Gut Permeability". The objectives of the study are to evaluate the safety and tolerability of oral administration of MB-102, and to evaluate the use of MB-102 as a means of measuring gut permeability in normal participants (n=10) and in those with radiologic evidence of small bowel Crohn's disease (n=10).
What is the current status of trial NCT03962998?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 22 participants. The study started on 2019-10-27. Estimated completion is 2021-10-05.
What conditions does trial NCT03962998 study?
This clinical trial studies the following conditions: Crohn Disease.
What interventions are being tested in trial NCT03962998?
The interventions under investigation include: Lactulose/Rhamnose solution (DRUG), MB-102 (DRUG).
Who is sponsoring clinical trial NCT03962998?
This trial is sponsored by MediBeacon, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03962998 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Crohn Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03962998's enrollment target sits among peer trials
22 60th of 71 higher than 12 of 71 other Crohn Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Crohn Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Cranberry and Gut Health in Crohn's Disease
RECRUITING · Early Phase 1
-
Effect of Statins on Crohn's Disease
RECRUITING · Early Phase 1
-
Stelara and Tremfya Pregnancy Exposure Registry OTIS Autoimmune Diseases in Pregnancy Project
RECRUITING
-
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
RECRUITING · Phase 1
-
Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission
RECRUITING · NA
-
Low Dose IL-2 for the Treatment of Crohn's Disease
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI